PTO/SB/21 (09-04) Approved for use through 07/31/2006: OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE dion Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 09/942.458 **TRANSMITTAL** Filing Date August 29, 2001 First Named Inventor **FORM** Larry A. LAREW Art Unit 1654 (to be used for all correspondence after initial filing) **Examiner Name** R. Teller Attorney Docket Number 8 + 9Total Number of Pages in This Submission 342312003801 references ENCLOSURES (Check all that apply) Fee Transmittal Form + duplicate After Allowance Communication Drawing(s) for fee processing - 2 pages Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information **Provisional Application** 

Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please **Extension of Time Request** Terminal Disclaimer Identify below): Form PTO/SB/08a/b + copy -**Express Abandonment Request** Request for Refund 2 pages 9 References Information Disclosure Statement CD, Number of CD(s) Return Receipt Postcard (Supplemental) - 3 pages Certified Copy of Priority Landscape Table on CD Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name MORRISON & FOERSTER LLP (Customer No. 25226) Signature Printed name Kimmerly A. Bolin Date Reg. No. April 25, 2005 44.546

I hereby certify that this correspondence	is being deposited with the L	J.S. Postal Service as Exp	oress Mail, Airbill No. EV 336620809 US
in an envelope addressed to: MS Amend shown below.	/ 1 '	/ I	xandria, VA 22313-1450, on the date
SHOWN BEIOW.	(2)	Chick	

Dated: April 25, 2005

(Georgina Matos)

APR 2 5 2005 35 4

PTO/SB/17 (12-04v2)
Approved for use through 7/31/2006. OMB 0651-0032 at and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are re on of information unless it displays a valid OMB control number. TRADEMA Complete if Known Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). Application Number 09/942,458 FEE TRANSMIT August 29, 2001 Filing Date First Named Inventor Larry A. LAREW For FY 2005 **Examiner Name** R. Teller Applicant claims small entity status. See 37 CFR 1.27 1654 Art Unit TOTAL AMOUNT OF PAYMENT 342312003801 180.00 Attorney Docket No. METHOD OF PAYMENT (check all that apply) Check Credit Card Money Order None Other (please identify): x Deposit Account Deposit Account Number: 03-1952 Deposit Account Name: Morrison & Foerster LLP For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) x Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayment of x Credit any overpayments fee(s) under 37 CFR 1.16 and 1.17 **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES** SEARCH FEES **EXAMINATION FEES** Small Entity **Small Entity** Small Entity **Application Type** Fee (\$) Fee (\$) Fee (\$) Fees Paid (\$) Fee (\$) Fee (\$) Fee (\$) Utility 300 150 500 250 200 100 0.00 Design 200 100 100 130 50 65 0.00 Plant 200 100 300 150 160 80 0.00 Reissue 300 150 500 250 600 300 0.00 Provisional 200 100 0 0 0 0 0.00 2. EXCESS CLAIM FEES **Small Entity** Fee Description Fee (\$) Fee (\$) Each claim over 20 (including Reissues) 50 25 Each independent claim over 3 (including Reissues) 200 100 Multiple dependent claims 360 180 Total Claims **Extra Claims** Fee Paid (\$) Multiple Dependent Claims 0.00 Fee Paid (\$) Fee (\$) 360 0.00 Extra Claims Fee (\$) Fee Paid (\$) 0 0.00 200 - 3 = 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). **Total Sheets** Extra Sheets Number of each additional 50 or fraction thereof Fee Paid (\$) Fee (\$) 250 - 100 = 0.00 (round up to a whole number) x 4. OTHER FEE(S) Fees Paid (\$) Non-English Specification, \$130 fee (no small entity discount) Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00 SUBMITTED BY Registration No Signature 44,546 Telephone (650) 813-5740 Name (Print/Type) Kimberly A. Bolin Date April 25, 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. MS Amendment, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA

2313-1450, on the date shown below.

Patent Docket No. 342312003801

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

E Patent Application of: Larry A. LAREW et al.

Serial No.: 09/942,458

Filing Date: August 29, 2001

ECHINOCANDIN/CARBOHYDRATE

**COMPLEXES** 

Examiner: R. Teller

Group Art Unit: 1654

## SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

Applicants would like to draw the Examiner's attention to the following co-pending application:

Application Serial No. 11/078,791, filed March 10, 2005, by Burkhardt et al.

04/27/2005 JBALINAN 00000045 031952 09942458

01 FC:1806

180.00 DA

	This Supp	elemental Information Disclosure Statement is submitted:
	With the	e application; accordingly, no fee or separate requirements are required.
	Before t	he mailing of a first Office Action after the filing of a Request for Continued
	Examina	ation under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) ha	as been provided.
	Within t	hree months of the application filing date or before mailing of a first Office Action
	on the m	nerits; accordingly, no fee or separate requirements are required. However, if
	applicab	ole, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
$\boxtimes$	After red	ceipt of a first Office Action on the merits but before mailing of a final Office Action
	or Notic	e of Allowance.
	. 🔲 E	A fee is required. A check in the amount of is enclosed.
	$\boxtimes$ A	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
	· t	his submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
	t	pelieved to be due.
	After ma	ailing of a final Office Action or Notice of Allowance, but before payment of the
	issue fee	· •.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
	а	amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
	f	Form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 342312003801.

Dated: April 25, 2005

Respectfully submitted,

Kimberly A. Bolin

Registration No.: 44,546

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304-1018

(650) 813-5740



Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many she ets as necessary)		Examiner Name	R. Teller	
1	of	1	Attorney Docket Number	342312003

Complete if Known			
Application Number	09/942,458		
Filing Date	August 29, 2001		
First Named Inventor	Larry A. LAREW		
Art Unit	1654		
Examiner Name	R. Teller		
Attorney Docket Number	342312003801		

	U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	1.	US-2004/0223997-A1	11-11-2004	Stogniew		

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)		Applicant of Cited Document	or Relevant Figures Appear	T <sup>6</sup>
	2.	JP-5-271097-A	10-19-1993	Asahi Chemical Industry Co. Ltd.	(Paterra Machine Translation)	<b>V</b>
	3.	JP-6-172205-A	06-21-1994	Asahi Chemical Industry Co. Ltd.	(Paterra Machine Translation)	√ ,
	4.	WO-03/105767-A2, A3	12-24-2003	Vicuron Pharmaceuticals, Inc.		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	5.	International Search Report for PCT Application No. PCT/US00/05494 filed March 2, 2000, mailed June 7, 2000, three pages.	
	6.	International Search Report for PCT Application No. PCT/US00/05508 filed March 2, 2000, mailed August 21, 2000, two pages.	
	7.	International Search Report for PCT Application No. PCT/US00/05546 filed March 2, 2000, mailed August 11, 2000, three pages.	
	8.	International Search Report for PCT Application No. PCT/US00/05547 filed March 2, 2000, mailed July 19, 2000, two pages.	
	9.	Keller-Juslen, C. et al. (1976). "Structure of the Cyclopeptide Antibiotic SL 7810 (=Echinocandin B)," <i>Tetrahedron Letters</i> 46:4147-4150.	
	10.	Turner, W.W. et al. (1996). "Recent Advances in the Medicinal Chemistry of Antifungal Agents," Current Pharmaceutical Design 2:209-224.	

<sup>\*</sup>EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.